Financial & Business News

Toronto, Ontario--(Newsfile Corp. - June 4, 2025) - STLLR Gold Inc. (TSX: STLR) (OTCQX: STLRF) (FSE: O9D) ("STLLR" or the "Company") is pleased to announce the remaining infill drilling results using artificial intelligence technology ("AI") at the Company's Tower Gold Project ("Tower") in the Timmins Mining Camp in Ontario, Canada. Table 1: 2025 Tower Infill Drilling Highlights - 903 and 55 Zone Deposits (For more information see Tables 2 & 3 and Figures 1-5): Zone Hole ID Assay Result 903 MGA25-237 2.61 g/t Au over 13.65 m (10.39 m TT)including 3.42 g/t Au over 2.80 m (2.13 m TT) including 5.30 g/t Au over 3.90 m (2.97 m TT) 903 MGA25-240 1.42 g/t Au over 11.15 m (7.27 m TT)Including 2.77 g/t Au over 2.30 m (1.50 m TT) and 1.33 g/t Au over 17.00 m (11.10 m TT) Including 1.85 g/t Au over 9.50 m (6.20 m TT) 903 MGA25-239 1.67 g/t Au over 10.85 m (7.75 m TT)Including 2.36 g/t Au over 4.50 m (3.21 m TT) 55 MGA25-542 2.18 g/t Au over 8.00 m (7.22 m TT)including 4.33 g/t Au over 3.40 m (3.

NEW YORK, NY / ACCESS Newswire / June 4, 2025 / If you suffered a loss on your Digimarc Corporation (NASDAQ:DMRC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/digimarc-corporation-lawsuit-submission-form-2?prid=151540&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / June 4, 2025 / If you suffered a loss on your Treace Medical Concepts, Inc. (NASDAQ:TMCI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/treace-medical-concepts-inc-lawsuit-submission-form-2?prid=151542&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq.

Zanubrutinib is currently best-in-class among BTK inhibitors for CLL, with superior efficacy and safety over ibrutinib and strong market momentum. Zanubrutinib will be in the leading position in CLL in the next 5 years, given the best-in-class BTK inhibitor and potential best combined regimen of zanubrutinib plus sonrotoclax in 2027. Pirtobrutinib maybe a powerful competitor to zanubrutinib when the phase 3 BRUIN CLL-314 trial PFS data is available in 2027.

U.S. tariffs on steel have only a limited direct effect on Thyssenkrupp Steel Europe, the company said on Wednesday, but the increase in import duties brings with it pressure on trade relations more broadly, it warned.

High-yield stocks are often riddled with flaws. However, there are some high-yield stocks available today that check all of my boxes. I share some of my top high-yield picks of the moment.

- Accomplished Global HR Executive with Deep Franchise and Healthcare Expertise, including CHRO Roles at Kimberly-Clark, Tenet Healthcare, and Yum! Restaurants International, to Join Board - - Accomplished Global HR Executive with Deep Franchise and Healthcare Expertise, including CHRO Roles at Kimberly-Clark, Tenet Healthcare, and Yum! Restaurants International, to Join Board -

Konoike Transport remains a buy despite global trade headwinds, supported by strong FY25 earnings growth and margin expansion across diversified business lines. The company's exposure to multiple industries, including logistics, airport services, and India's market, offers resilience and long-term growth opportunities. Recent results showed a 9.5% sales increase and 18.9% gross profit growth, but future risks from trade disruptions persist.

The price-to-earnings (P/E) ratio is one of the most widely used tools to evaluate a stock's valuation and is quite easy to understand. It simply divides a company's current share price by its earnings per share (EPS), providing insight into how richly or conservatively a company is being valued by the market.

Chinese electric vehicle battery giant CATL said on Wednesday that it would partner with a unit of Danish shipping firm Maersk , APM Terminals, on the development and after-sales support of advanced battery products.